Immunogen (IMGN) has released an update.
ImmunoGen, Inc. has agreed to a merger with AbbVie, with ImmunoGen becoming a subsidiary post-merger. A definitive proxy statement was filed with the SEC, and four shareholder complaints alleging omissions and misrepresentations in the Proxy Statement were subsequently filed. ImmunoGen disputes these claims but has made supplemental disclosures to the Proxy Statement to avoid litigation risks and potential merger delays. These disclosures will not affect the merger consideration or the timing of the shareholder meeting, where ImmunoGen shareholders will vote on the merger. The supplemental information is available on the SEC’s website and should be read alongside the original Proxy Statement.
For further insights into IMGN stock, check out TipRanks’ Stock Analysis page.
